This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pfizer Seeks to Raise Coronavirus Study Enrollment Target
by Zacks Equity Research
Pfizer (PFE) and its partner, BioNTech, are seeking FDA's approval to increase enrollment target in the late-stage study on their coronavirus vaccine candidate to diversify patient population.
AstraZeneca Resumes UK Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in U.K. resume after the Medicines Health Regulatory Authority confirms that it is safe to do so.
Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals
by Kinjel Shah
AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.
Pfizer, BioNTech May Supply 200M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech are in discussion with the European Commission to supply potentially 200 million doses of their COVID-19 vaccine BNT162b2 on approval.
Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Pausing of AstraZeneca's Coronavirus Study Aids Pfizer, Moderna
by Indrajit Bandyopadhyay
The pause in AstraZeneca's (AZN) voluntary coronavirus study following an adverse event provides its competitors a breather.
3 Safe Blue Chip Stocks to Buy as Market Bounces Back After Tech Selloff
by Benjamin Rains
There could be more selling ahead and the election might cause turbulence. Nonetheless, long-term investors might want to consider adding a few safe blue chip stocks to their portfolios...
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.18, marking a +0.7% move from the previous day.
Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe
by Zacks Equity Research
Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.
Moderna Gets Rating Downgrade, Takes Safety Pledge, Stock Down
by Zacks Equity Research
Moderna (MRNA) pledges with eight other pharma companies to ensure commercialization of a safe and effective vaccine. However, anticipated competitive pressure weighs on the stock.
CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge
by Kinjel Shah
The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.
Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study
by Kinjel Shah
Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.
Coronavirus Vaccine Makers May Make Joint Safety Pledge
by Kinjel Shah
The vaccine developers are likely to pledge to observe high ethical standards in conducting clinical studies and manufacturing of the vaccines, the Wall Street report said.
Pharma Stock Roundup: SNY, GSK, AZN's Coronavirus Vaccines/Treatments Progress
by Kinjel Shah
AstraZeneca (AZN) begins phase III study on COVID-19 vaccine candidate in the United States. Sanofi (SNY)/Glaxo's (GSK) vaccine enters clinical stage.
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity
by Zacks Equity Research
Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).
Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod
by Zacks Equity Research
Arena (ARNA) doses first patients in a phase II study evaluating etrasimod in patients with alopecia areata.
AstraZeneca's Imfinzi Gets EU Approval for First-Line SCLC
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi gets approval in Europe to treat extensive-stage small cell lung cancer.
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
Novavax to Supply Coronavirus Vaccine to Canadian Government
by Zacks Equity Research
Novavax (NVAX) signs a contract with the Government of Canada for supplying up to 76 million doses of its COVID-19 vaccine NVX-CoV2373, if approved.
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
by Zacks Equity Research
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
Stock Market News for Sep1, 2020
by Zacks Equity Research
U.S. stock markets closed mostly lower on Monday as investors booked profit after a week-long rally.
Lessons for Equity Investors From Dow Jones' Big Shake-Up
by Nilanjan Choudhury
The Dow Jones is a rare example of an index constructed on the basis of a component's share price.
AstraZeneca Begins Coronavirus Vaccine US Phase III Study
by Zacks Equity Research
AstraZeneca's(AZN) phase III study to enroll 30,000 adult participants and assess the safety, efficacy and immunogenicity of its COVID-19 vaccine candidate, AZD1222.
Bull of the Day: Salesforce.com (CRM)
by David Borun
This brand-new Dow component continues to beat the estimates and raise guidance.